Oxidative Stress and Its Molecular Effectors in Uterine Smooth Muscle Tumors: Bridging Epigenetic Regulation and Glycoprotein Biomarkers

1. Introduction

Cancers of the female reproductive tract present complex diagnostic and therapeutic hurdles, particularly concerning mesenchymal neoplasms originating in the myometrium. Uterine leiomyomas represent the most frequent benign tumors in women of reproductive age, affecting 15–25% of women clinically and reaching an epidemiological prevalence of up to 70% by age 50 [1]. These benign tumors cause significant morbidity, presenting with symptoms that include abnormal uterine bleeding (menorrhagia), severe pelvic pain, dysmenorrhea, pressure on adjacent organs leading to urinary or bowel dysfunction, and significant challenges with fertility [1].

In stark contrast to these benign lesions, uterine sarcomas are exceedingly rare, comprising approximately 3% of all uterine cancers [2,3]. Despite their rarity, these malignancies are highly aggressive, characterized by rapid cellular proliferation, early hematogenous dissemination, and a dismal prognosis. Epidemiological data indicate that uLMS predominantly affects peri- and postmenopausal women, with a median age at diagnosis between 50 and 55 years [4]. The incidence rate of uLMS ranges from a mere 0.36 to 0.64 per 100,000 women annually [4]. Five-year survival rates for uLMS are exceptionally poor, ranging from 18.8% to 65%, with recurrence rates soaring between 53% and 71% even after complete surgical resection. Risk factors for these aggressive sarcomas remain scarcely defined but include hereditary retinoblastoma, Li-Fraumeni syndrome (inherited TP53 mutations), prior pelvic exposure to radiation, and the therapeutic administration of tamoxifen [3,4]. Between these two extremes of benign and malignant disease lies a transitional category known as smooth muscle tumors of uncertain malignant potential (STUMP), which exhibit overlapping histopathological features and an unpredictable clinical course characterized by occasional metastasis [5].

The preoperative differentiation of benign leiomyomas from uLMS and STUMP remains a profound clinical dilemma. Current diagnostic methodologies rely heavily on clinical evaluation and imaging techniques, such as ultrasound and magnetic resonance imaging (MRI), which frequently exhibit substantial overlapping features. Consequently, a definitive diagnosis is predominantly established postoperatively following the meticulous histopathological examination of the surgically excised specimen. This diagnostic ambiguity poses severe clinical risks; the inadvertent use of minimally invasive surgical techniques, specifically laparoscopic power morcellation, can inadvertently disseminate occult malignant tissue throughout the peritoneal cavity, drastically worsening patient outcomes [6].

To address this critical diagnostic gap, contemporary research has pivoted toward the molecular landscape of these tumors. Oxidative stress has emerged as a fundamental driver of oncogenesis in the female reproductive tract. The imbalance between reactive oxygen species (ROS) production and cellular antioxidant defense mechanisms induces severe DNA damage and genomic instability, accelerating malignant transformation [7]. This manuscript provides a comprehensive review of the pathogenesis of uterine smooth muscle tumors, positioning oxidative stress as the central pathophysiological hub that links genomic instability, epigenetic dysregulation via miRNAs, and the expression of circulating glycoprotein biomarkers.

2. Anatomical and Physiological Microenvironment

2.1. Uterine Anatomy and the Myometrial Structure

The uterus is a hollow, muscular organ centrally located in the lesser pelvis, situated precisely between the urinary bladder anteriorly and the rectum posteriorly. Anatomically, it is divided into three primary sections: the body (corpus), the isthmus, and the cervix. The uterine cavity maintains a triangular shape within the corpus and directly communicates with the fallopian tubes via the bilateral tubal ostia. The organ is securely maintained in its anatomical position by a highly complex supportive mechanism consisting of the broad ligaments, uterosacral ligaments, transverse ligaments, and round ligaments. These ligamentous structures work in essential conjunction with the pelvic floor muscles and fascia to support the pelvic organs [8].

The uterine wall consists of three distinct microscopic layers:

Endometrium: The inner mucosal layer that undergoes profound cyclical changes during the menstrual cycle. It is functionally divided into a basal layer and a functional layer, the latter of which is shed during menstruation and regenerates sequentially from the basal layer.

Myometrium: The thickest layer of the uterine wall, strictly composed of smooth muscle fibers. These fibers are organized in diverse and overlapping orientations, including longitudinal, circular, and oblique bundles. This intricate structural organization allows for the generation of strong, coordinated contractions necessary for endometrial shedding, the maintenance of pregnancy, and parturition.

Perimetrium: The outer serous layer, representing a direct extension of the peritoneum that covers the majority of the uterine surface.

The vascular supply to this highly metabolically active tissue is primarily provided by the uterine arteries, which are direct branches of the internal iliac arteries. These arteries branch extensively within the myometrium to form specialized arcuate and radial arteries that supply the underlying endometrium. Innervation is derived from the autonomic nervous system via the hypogastric plexus, encompassing both sympathetic and parasympathetic fibers that meticulously regulate muscular and vascular function [8].

2.2. Hormonal Regulation and Dysregulation

The functional integrity of the myometrium is heavily regulated by complex hormonal, neural, and local signaling networks. Estrogens stimulate the rapid proliferation of myometrial cells, while progesterone primarily drives cellular differentiation and functional maturation. The disruption of these signaling pathways, compounded by oxidative cellular stress, leads to abnormal cellular proliferation and the excessive deposition of extracellular matrix. This specific hormonal and oxidative interplay precipitates the formation and sustained growth of uterine leiomyomas [9].

3. Histopathological and Clinical Classifications

The World Health Organization (WHO) and the International Federation of Gynecology and Obstetrics (FIGO) provide the standard frameworks for classifying these tumors, relying heavily on morphological criteria and anatomical positioning [10].

3.1. Benign Tumors: Leiomyoma Subtypes

Leiomyomas are characterized by well-differentiated smooth muscle cells, minimal cytologic atypia, low mitotic indices, and a complete absence of tumor cell necrosis. The WHO recognizes several morphological subtypes that hold particular diagnostic significance:

-

Classic (usual) leiomyoma.

-

Cellular leiomyoma, which features dense cellularity but lacks malignant criteria.

-

Atypical or bizarre leiomyoma, which may mimic malignancy due to nuclear pleomorphism.

-

Mitotically active leiomyoma, showing increased mitotic counts but lacking atypia or necrosis.

-

Epithelioid leiomyoma.

-

Myxoid leiomyoma [10].

Furthermore, the FIGO PALM-COEIN system classifies leiomyomas anatomically to

guide surgical intervention:

Type 0: Pedunculated intracavitary leiomyoma without intramural extension.

Type 1: Submucosal leiomyoma with less than 50% intramural extension.

Type 2: Submucosal leiomyoma with 50% or more intramural extension.

Type 3: Intramural leiomyoma in direct contact with the endometrium, not protruding into the cavity.

Type 4: Purely intramural leiomyoma.

Type 5: Subserosal leiomyoma with 50% or more intramural involvement.

Type 6: Subserosal leiomyoma with less than 50% intramural involvement.

Type 7: Pedunculated subserosal leiomyoma.

Type 8: Leiomyomas of other specified locations (e.g., cervical, intraligamentary) [11].

3.2. Smooth Muscle Tumors of Uncertain Malignant Potential (STUMP)

STUMPs constitute a diagnostically challenging entity featuring atypical morphology that does not completely satisfy the criteria for outright malignancy. Diagnosis relies strictly on evaluating the degree of cellular atypia, the exact mitotic activity, and the presence or absence of tumor cell necrosis. Their clinical behavior is notoriously unpredictable. While most STUMPs follow a relatively benign course, they carry a documented recurrence rate ranging from 8.7% to 11%. Recurrences may present as recurrent STUMP or, more dangerously, undergo malignant transformation into fully aggressive leiomyosarcomas [5].

3.3. Malignant Counterparts: uLMS and Associated Sarcomas

Malignant neoplasms of the myometrium primarily include leiomyosarcomas, endometrial stromal sarcomas (ESS), and undifferentiated uterine sarcomas:

Uterine Leiomyosarcoma (uLMS): Diagnosis depends rigidly on the Stanford criteria, requiring at least two of the following morphological features: diffuse and severe cytologic atypia, a high mitotic index (typically greater than 10 mitoses per 10 high-power fields), and coagulative tumor cell necrosis [12]. uLMS typically expresses definitive smooth muscle markers such as desmin, smooth muscle actin (SMA), and h-caldesmon. They frequently demonstrate a marked loss of estrogen and progesterone receptor (ER and PR) expression, rendering hormonal therapies ineffective [2,3]. Subtypes include epithelioid leiomyosarcoma and myxoid leiomyosarcoma, the latter of which may exhibit lower apparent mitotic activity, drastically complicating the histopathological diagnosis.

Endometrial Stromal Sarcoma (ESS): Differentiated into low-grade and high-grade malignancies, originating from the endometrial stroma. Low-grade ESS often expresses hormonal receptors and exhibits an indolent but recurrent course, whereas high-grade ESS is highly aggressive.

Undifferentiated Uterine Sarcoma: A rare, extraordinarily aggressive neoplasm characterized by a complete absence of histological differentiation, severe atypia, and extensive necrosis.

4. Oxidative Stress: The Engine of Genomic Instability

The progression from a normal myometrial cell to a highly aggressive sarcoma is deeply underpinned by a profound deterioration of genomic integrity. Oxidative stress serves as the primary catalyst and continuous engine for this deterioration.

4.1. Markers of Oxidative Burden in Uterine Tumors

The tumor microenvironment in uLMS and even rapidly growing leiomyomas is characterized by a severe imbalance in oxidative homeostasis.

Oxidative stress is defined as the chronic disruption of the equilibrium between reactive oxygen species (ROS) production and the body’s endogenous antioxidant defenses. Clinical studies have revealed a significant increase in systemic and local protein oxidative stress status in women harboring uterine leiomyomas. Specific markers of oxidative stress, notably lipid peroxidation products such as malondialdehyde (MDA), have been extensively studied and are highly elevated in leiomyosarcomas. Concentrations of serum protein carbonyl groups and advanced oxidized protein products (AOPP) are significantly higher in leiomyoma patients compared to healthy controls. By contrast, serum thiol levels, which reflect critical antioxidant capacity, are markedly lower in patients harboring uterine tumors [7].

The ratio of reduced to oxidized glutathione serves as an additional critical indicator of the cellular oxidative state in these tumors.

Leiomyoma cells frequently exhibit lower expression of antioxidant enzymes, such as superoxide dismutase (SOD) and catalase (CAT), compared to normal uterine muscle cells, specifically in hypoxic environments.

Transcriptome-combined Mendelian randomization analyses have identified highly specific oxidative stress-related biomarkers in uterine leiomyoma, establishing genes such as ANXA1, CD36, MICB, and PRDX6 as critical mediators in tumor risk stratification [13].

Increased oxidative stress is directly correlated with the accumulation of severe DNA damage.

This persistent DNA damage translates into broad genomic instability, ultimately leading to the evolution of the malignant phenotype in uterine smooth muscle tumors.

4.2. Metabolic Reprogramming and Hypoxia

The profound oxidative stress observed in uLMS is closely tied to the metabolic reprogramming of the tumor, specifically the metabolic shift toward anaerobic glycolysis known as the Warburg effect [14]. Lactate dehydrogenase (LDH) is a key enzyme in this process, converting pyruvate to lactic acid under anaerobic conditions. LDH consists of five distinct isoenzymes (LDH-1 through LDH-5), formed by unique combinations of H (heart) and M (muscle) subunits. LDH-1 is prevalent in cardiac tissue; LDH-2 in the reticuloendothelial system; LDH-3 in the lungs; LDH-4 in the kidneys; and LDH-5 predominantly in the liver and skeletal muscle. In sarcomas of smooth muscle origin, there is a characteristic, pathological elevation in the LDH-4 and LDH-5 isoenzymes. The predominance of the LDH-5 isoenzyme is heavily associated with severely hypoxic regions within the tumor microenvironment [15]. Furthermore, elevated LDH-5 correlates precisely with aggressive malignant behavior, rapid cellular proliferation, and an increased propensity for distant metastasis. The Magna Graecia score attempts to utilize this metabolic shift by combining serum LDH levels with MRI characteristics, tumor growth rates, and menopausal status to improve preoperative diagnosis. This scoring system places particular clinical emphasis on the LDH-5 imbalance as a strong, independent indicator of malignancy [16].

4.3. Mutational Landscape and Genomic Consequences

The severe genomic instability fueled by chronic oxidative stress manifests as a distinct and highly volatile mutational landscape in uLMS.

TP53, a critical tumor suppressor gene responsible for cell cycle regulation and DNA repair, is mutated or deleted in 60% to 80% of all uLMS cases [17].

Inactivation of the RB1 gene occurs in approximately 50% of these tumors, further dismantling essential cell cycle checkpoints [17].

Alterations in the ATRX gene are found in 25% to 35% of uLMS cases and are intrinsically linked to the alternative lengthening of telomeres (ALT).

This ALT mechanism bypasses standard cellular senescence, conferring replicative immortality to the cancer cells [18].

Frequent mutations are also observed in PTEN, MED12, CDKN2A, and genes regulating the PI3K/AKT/mTOR signaling pathway.

Cytogenetically, uLMS reveals complex, highly aneuploid karyotypes featuring frequent chromosomal additions at 1q and 17p, and critical deletions at chromosome 10q (the PTEN locus) and 13q14 (the RB1 locus) [18].

5. Epigenetic Dysregulation in the Stressed Microenvironment

The genomic instability and oxidative stress inherent to uLMS create a highly dysregulated epigenetic landscape, primarily characterized by aberrant microRNA (miRNA) expression.

5.1. miRNA Biogenesis and Extracellular Stability

miRNAs are small, non-coding RNAs comprising approximately 18 to 25 nucleotides that modulate gene expression post-transcriptionally [19].

The biogenesis of miRNAs begins in the nucleus with the transcription of primary miRNAs (pri-miRNAs) by RNA polymerase II. These are processed by the Drosha-DGCR8 microprocessor complex into 70-nucleotide precursor miRNAs (pre-miRNAs). Pre-miRNAs are exported to the cytoplasm via Exportin-5, where they undergo enzymatic cleavage by Dicer to produce mature double-stranded miRNA duplexes [20].

The guide strand is incorporated into the RNA-induced Silencing Complex (RISC) to direct target mRNA recognition, while the passenger strand is typically degraded.

miRNAs are extraordinarily stable in the extracellular environment. They circulate securely protected from endogenous RNases by associating with proteins such as Argonaute 2 (Ago2) or high-density lipoproteins (HDL), or by encapsulation within extracellular vesicles (EVs) and exosomes. This structural protection allows miRNAs to withstand harsh physical conditions, including multiple freeze-thaw cycles and extremes of pH, making them ideal targets for non-invasive liquid biopsies detected via RT-qPCR, microarray, next-generation sequencing (NGS), and digital droplet PCR (ddPCR) [19].

5.2. Downregulation of Tumor-Suppressive miRNAs

The oxidative and hypoxic tumor microenvironment frequently silences miRNAs that normally act as tumor suppressors, thereby removing the brakes on cellular proliferation and invasion.

Expression of the miR-29 family is significantly and consistently downregulated in uLMS tissue. miR-29b is responsible for targeting essential oncogenes, including AKT3 and CDK6, as well as extracellular matrix (ECM) remodeling genes. The severe loss of miR-29 expression directly contributes to the hyperactivation of oncogenic signaling cascades and is robustly associated with poor patient prognosis [21].

Oxidative stress and hypoxia are known drivers of epithelial-mesenchymal transition (EMT). The miR-200 family (which includes miR-200a, miR-200b, miR-200c, miR-141, and miR-429) normally acts to inhibit EMT by directly targeting the potent transcription factor ZEB1 [22]. The downregulation of the miR-200 family in uLMS directly facilitates the acquisition of an invasive, mesenchymal phenotype and dramatically promotes metastasis.

The let-7 Family of miRNAs suppresses multiple highly active oncogenes, including HMGA2, RAS, and MYC [23]. The profound downregulation of let-7 in uLMS eliminates crucial growth suppression mechanisms, leading directly to highly aggressive disease.

Additional Suppressors such as miR-34a and miR-181b specifically function to inhibit invasion and cellular migration in uterine mesenchymal tumors; their loss contributes heavily to the metastatic potential of the sarcoma. Similarly, the downregulation of miR-10b-5p enhances proliferation and correlates with a highly aggressive phenotype. Downregulation of miR-126 removes the suppression of VEGF, leading to uninhibited angiogenesis.

5.3. Upregulation of Oncogenic miRNAs (OncomiRs)

Conversely, the stressed microenvironment triggers the rampant overexpression of specific miRNAs that intensely drive tumor survival.

One of the most consistently and heavily overexpressed miRNAs in uLMS is miR-21. It functions as a potent oncomiR by directly targeting and inhibiting critical tumor suppressors such as PTEN and PDCD4 [24]. The concurrent upregulation of miR-21 (which actively suppresses PTEN) and the downregulation of miR-29 (which fails to suppress AKT3) creates a powerful, synergistic hyperactivation of the PI3K/AKT/mTOR signaling pathway. This pathway is central to tumor cell survival, uninhibited proliferation, and profound immune evasion.

The miR-183~96~182 Cluster is highly and specifically upregulated in uLMS. Specifically, miR-182 strongly targets tumor suppressors like FOXO1, exponentially enhancing the migratory capacity of the cells. This cluster serves as an established prognostic biomarker for an elevated risk of metastasis [25].

Overexpression of the miR-221/222 specific cluster is heavily implicated in severe cell cycle dysregulation and is directly associated with broad chemotherapy resistance across various sarcomas and gynecologic tumors [26].

Table 1. Key Epigenetic Signatures in Uterine Leiomyosarcoma.

miRNA Signature	Expression Profile	Validated Target Genes	Biological Consequence
miR-29 Family	Downregulated	AKT3, CDK6, ECM genes	Loss of tumor suppression; PI3K pathway hyperactivation.
miR-200 Family	Downregulated	ZEB1	Loss of EMT suppression; increased metastatic potential.
let-7 Family	Downregulated	HMGA2, RAS, MYC	Uncontrolled cell cycle progression; highly aggressive disease.
miR-21	Upregulated	PTEN, PDCD4	OncomiR activity; hyperactivation of PI3K/AKT/mTOR survival pathway.
miR-183~96~182	Upregulated	FOXO1	Enhanced migratory capacity; high risk of distant metastasis.
miR-221/222	Upregulated	Cell cycle regulators	Promotion of proliferation and mediation of profound chemoresistance.

Table 1. Key Epigenetic Signatures in Uterine Leiomyosarcoma.

miRNA Signature	Expression Profile	Validated Target Genes	Biological Consequence
miR-29 Family	Downregulated	AKT3, CDK6, ECM genes	Loss of tumor suppression; PI3K pathway hyperactivation.
miR-200 Family	Downregulated	ZEB1	Loss of EMT suppression; increased metastatic potential.
let-7 Family	Downregulated	HMGA2, RAS, MYC	Uncontrolled cell cycle progression; highly aggressive disease.
miR-21	Upregulated	PTEN, PDCD4	OncomiR activity; hyperactivation of PI3K/AKT/mTOR survival pathway.
miR-183~96~182	Upregulated	FOXO1	Enhanced migratory capacity; high risk of distant metastasis.
miR-221/222	Upregulated	Cell cycle regulators	Promotion of proliferation and mediation of profound chemoresistance.

6. Glycoprotein Biomarkers: Effectors of the Oxidative TME

The oxidative and hypoxic conditions within the uLMS microenvironment also dictate the expression of surface and circulating glycoproteins, which actively mediate angiogenesis, immune evasion, and metastasis. Two primary glycoproteins have been heavily investigated for their diagnostic potential: galectin-1 and mucin-1 (MUC1).

6.1. Galectin-1: A Diagnostic Marker of the Aggressive Phenotype

Galectin-1 is a β-galactoside-binding lectin that plays a pivotal and multifaceted role in the tumor’s adaptation to extreme oxidative stress.

Pathophysiology: Galectin-1 is overexpressed in various neoplasms, including aggressive smooth muscle tumors. Within the highly stressed tumor microenvironment, it actively enhances angiogenesis via VEGF-dependent mechanisms. Furthermore, it creates a profoundly immunosuppressive environment by directly inducing apoptosis in activated T-lymphocytes, altering the delicate Th1/Th2 balance, and promoting deep immunological tolerance, allowing the sarcoma to seamlessly evade immune destruction [27].

Clinical Diagnostic Performance: A comprehensive, prospective case-control study analyzed serum samples from 156 women, comprising 49 healthy controls, 90 patients with benign uterine myomas, and 17 patients with aggressive uterine sarcomas or STUMPs. The study found that serum galectin-1 concentrations are significantly and consistently higher in patients with uterine sarcomas and STUMPs compared to both healthy controls and patients with benign leiomyomas (p = 0.002). In stringent multivariable logistic regression analyses, adjusted for critical clinical variables such as patient age and menopausal status, galectin-1 remained independently and strongly associated with the presence of sarcoma (OR 1.07 per 1,000-unit increase; 95% CI 1.02–1.13; p = 0.007). Receiver operating characteristic (ROC) curve analysis rigorously evaluated its diagnostic accuracy. The analysis revealed a moderate discriminative ability for galectin-1, yielding an Area Under the Curve (AUC) of 0.78 when distinguishing sarcomas from healthy controls, and an AUC of 0.72 when comparing sarcomas to all non-sarcoma cases combined. Crucially, at its optimal calculated cutoff value, galectin-1 achieved an exceptional specificity of 100%, indicating an unparalleled capacity to “rule in” malignancy and prevent misdiagnosis. However, its sensitivity was limited to exactly 47%, necessitating its use alongside other robust diagnostic parameters [28].

6.2. Mucin-1 (MUC1): Limited Utility in Mesenchymal Tumors

MUC1 is a highly glycosylated, high-molecular-weight transmembrane protein normally expressed on apical epithelial surfaces to maintain physical barrier integrity.

Pathophysiology in Cancer: In many epithelial malignancies (such as ovarian and breast carcinomas), MUC1 is profoundly aberrantly glycosylated and overexpressed [29]. This distinct structural change directly reduces cellular adhesion, drastically increases cellular mobility, and creates a dense hydrophilic barrier that can physically impede chemotherapeutic drug uptake. Furthermore, aberrantly glycosylated MUC1 directly inhibits the cytotoxic actions of natural killer (NK) cells and CD8+ T-lymphocytes, facilitating broad immune escape. MUC1 also actively interacts with intracellular survival pathways, including PI3K/AKT and MAPK [30].

Diagnostic Performance in uLMS: Despite its established and vital role in epithelial cancers, MUC1 lacks diagnostic utility in uterine mesenchymal tumors.

The aforementioned clinical study evaluated circulating serum MUC1 levels across the 156-patient cohort and found no statistically significant differences between healthy controls, myoma patients, and sarcoma patients (p = 0.178). MUC1 was definitively not independently associated with sarcoma in any adjusted multivariable analysis. ROC curve analysis confirmed its poor discriminative ability, yielding an AUC of only 0.59 for distinguishing sarcomas from healthy controls [28].

6.3. Additional Inflammatory and Serum Markers

Elevated C-Reactive Protein (CRP) in uLMS patients strongly correlates with a highly inflammatory microenvironment and extensive tissue necrosis. However, it lacks diagnostic specificity, as it rises in numerous benign conditions.

The overexpression of pro-inflammatory cytokines like IL-6 and IL-8 promotes rampant angiogenesis and cellular proliferation. Their clinical use remains strictly experimental.

While critical in ovarian cancer, CA-125 has limited and non-specific utility in uterine smooth muscle tumors. Mild to moderate elevations may occur due to peritoneal irritation, localized inflammation, or tumor necrosis, rather than direct tumor secretion.

7. Clinical Translation and Future Directions

The integration of oxidative stress markers, epigenetic profiles, and glycoprotein levels presents a transformative and urgent approach to the clinical management of uterine smooth muscle tumors.

7.1. Enhancing Preoperative Diagnostics and Imaging

Currently, transvaginal ultrasound and MRI serve as the primary clinical imaging modalities, but they cannot definitively or reliably differentiate benign from malignant disease [31].

The MYLUNAR (MYometrial Lesion UltrasouNd And mRi) study attempts to rectify this by utilizing specific ultrasound parameters (e.g., highly irregular margins, internal cystic degeneration, elevated vascular Doppler parameters like Resistance Index and Pulsatility Index) to flag suspicious masses. This is combined with MRI functional indicators, specifically Diffusion-Weighted Imaging (DWI) and the Apparent Diffusion Coefficient (ADC). Low ADC values frequently correlate directly with the dense cellularity characteristic of potential malignancy [31]. Furthermore, Dynamic Contrast-Enhanced MRI (DCE-MRI) assesses tumor angiogenesis and severe vascular permeability.

However, these imaging modalities must be augmented by precise molecular liquid biopsies. Circulating miRNAs, due to their robust encapsulation in exosomes or binding to protective proteins, exhibit remarkable stability in peripheral blood, resisting degradation from endogenous RNases. Specific circulating miRNAs, such as elevated serum miR-1246 and miR-191-5p, show significant clinical promise as non-invasive biomarkers for uLMS [32].

Furthermore, a targeted tissue-based panel consisting specifically of miR-144-3p, miR-34a-5p, and miR-206 has been identified to accurately distinguish uLMS from benign leiomyomas [33]. Combining these stable epigenetic signatures with highly specific glycoprotein markers like galectin-1, alongside traditional LDH-5 isoenzyme profiling and the Magna Graecia score, could create a robust, multimarker preoperative diagnostic panel.

7.2. Guiding Surgical Management and the Morcellation Controversy

The severe absence of reliable preoperative diagnostics directly impacts surgical safety and patient survival. For highly benign, symptomatic leiomyomas, treatments are individualized, ranging from hysteroscopic myomectomy for Type 0 and Type 1 fibroids, to laparoscopic myomectomy or total hysterectomy. Because aggressive uLMS is frequently diagnosed incidentally following minimally invasive surgery for presumed benign fibroids, the use of uncontained laparoscopic power morcellation carries a grave and well-documented risk of rapid tumor upstaging and intraperitoneal dissemination. In response to these severe risks, the FDA issued strict safety communications in 2014 and updated guidance in 2020, strongly recommending against the use of power morcellation in the majority of women. When absolutely necessary, the FDA mandates utilizing specialized containment systems only in carefully selected, definitively low-risk patients [6].

The implementation of the aforementioned multimarker molecular panels—specifically utilizing galectin-1’s 100% specificity—would empower clinicians to accurately identify high-risk patients preoperatively. This ensures they receive total hysterectomy with en bloc resection and appropriate oncological staging, entirely avoiding iatrogenic dissemination.

7.3. Targeted Therapeutics and ROS-Inducing Agents

For advanced or recurrent uLMS, systemic chemotherapy regimens (including Doxorubicin, often combined with ifosfamide, or gemcitabine plus docetaxel) remain the standard of care, alongside agents like trabectedin, dacarbazine, and pazopanib. Yet, they offer only modest progression-free survival.

Understanding the profound molecular pathways driven by oxidative stress opens radically new therapeutic avenues. Preclinical research demonstrates that inducing fatal levels of oxidative stress via proteasome inhibition using bortezomib severely impacts uLMS cell lines (e.g., SK-LMS-1 and SK-UT-1B). Bortezomib treatment induces massive reactive oxygen species production and profound mitochondrial membrane depolarization. This oxidative collapse leads to Annexin V-positive apoptotic cell death, massive lactate dehydrogenase release, enhanced cleavage of PARP and caspase-3, and severe G2/M cell cycle arrest modulated by p21 and p53. Furthermore, bortezomib dramatically alters autophagic processing, marked by the rapid accumulation of LC3B-II and p62 [34].

The hyperactivation of the PI3K/mTOR pathway—a direct result of PTEN suppression by overexpressed miR-21 and AKT3 uninhibited by the severe loss of miR-29—represents another primary, highly actionable therapeutic target. Preclinical evidence decisively demonstrates that inhibiting the PI3K/mTOR pathway physically remodels the immunosuppressive tumor microenvironment and successfully sensitizes the sarcoma to PD-1 immune checkpoint blockade [35]. Additionally, miRNA-based therapeutics are under intense clinical investigation. Synthetic miRNA mimics aim to artificially replenish lost tumor suppressors (e.g., miR-34a mimics) [36], while specialized antagomiRs and locked nucleic acid (LNA) inhibitors are designed to effectively silence oncogenic drivers like miR-221/222, potentially reversing the aggressive tumor phenotype and fully restoring targeted chemosensitivity.

8. Conclusion

Uterine leiomyosarcoma is an extraordinarily aggressive, highly heterogeneous malignancy characterized by profound genomic instability and a dismal clinical prognosis. The fundamental driver of this continuous genomic deterioration is an inherently stressed tumor microenvironment, deeply marked by severely altered antioxidant defenses, elevated lipid peroxidation (MDA), and hypoxia-driven metabolic reprogramming (Warburg effect and LDH-5 elevation). This massive oxidative burden serves as the primary catalyst for widespread epigenetic dysregulation, specifically driving the dangerous suppression of tumor-protective miRNA families (miR-29, miR-200, let-7) and the rampant, unchecked overexpression of oncogenic miRNAs (miR-21, miR-183~96~182).

Simultaneously, this stressed microenvironment actively promotes the heavy expression of galectin-1, a powerful glycoprotein that facilitates intense angiogenesis and absolute immune evasion. In rigorous clinical application, galectin-1 serves as a highly specific (100%), circulating biomarker exceptionally capable of identifying patients with occult uterine sarcomas preoperatively, a complex diagnostic context where traditional markers like MUC1 entirely fail.

To definitively overcome the diagnostic “gray zone” that currently plagues the surgical management of uterine smooth muscle tumors, future oncological research must prioritize the rigorous standardization of oxidative stress assays and their direct integration with circulating miRNA signatures and galectin-1 quantification. By successfully bridging these interconnected molecular domains, clinicians can rapidly develop robust, non-invasive liquid biopsies that ensure accurate preoperative risk stratification, dictate overwhelmingly safe surgical practices free from morcellation risks, and pave the way for precision-targeted therapeutics in the future of gynecological oncology.